Blood
Articles in this Issue
A niche for every stem cell in myeloproliferative neoplasms
VEXAS anemia is a mosaic erythroblastopenia
Abstract VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome is a recently discovered autoinflammatory disorder linked to somatic mutations in the UBA1 gene,...
Long-term follow-up of gastrointestinal CAR T-cell lymphoma: homing, clonal expansion, and response to cyclosporine
Abstract Chimeric antigen receptor (CAR) T-cell therapy has emerged as a transformative treatment for hematological malignancies, yet its potential to drive lymphomagenesis poses s...
Graft manipulation and GVHD: what goes around comes around
A mechanism for a VEXing problem
Orca-T vs allogeneic hematopoietic stem cell transplantation (Precision-T): a multicenter, randomized phase 3 trial
Abstract To prevent graft-versus-host disease (GVHD) in patients undergoing myeloablative allogeneic hematopoietic stem cell transplantation (alloHSCT), a calcineurin inhibitor plu...
Pediatric acute erythroid leukemia with <i>NUP98</i> :: <i>KDM5A</i> fusion
Lichtman MA, Rowe JM. Hyperleukocytic leukemias: rheological, clinical, and therapeutic considerations. <i>Blood</i> . 1982;60(2):279-283.
2025 update on MRD in acute myeloid leukemia: a consensus document from the ELN-DAVID MRD Working Party
Abstract Measurable residual disease (MRD) monitoring has become a critical component in the management of acute myeloid leukemia (AML), to inform prognosis, guide therapy, and ser...
Gene expression profiling reveals 2 overarching types of ALCL with distinct targetable biology: an LLMPP study
Abstract Anaplastic large cell lymphomas (ALCLs) are CD30+ T-cell lymphomas that share pathologic features but differ in presentation, outcome, and genetics. Current classification...
Microenvironmental cell interactions are essential for sustaining functionality of myelofibrosis malignant stem cells
Abstract Cancer develops through the interactions between cancer stem cells and components of the tumor microenvironment (TME). To model in vivo cancer stem cell–TME interactions a...
When CAR T cells become the disease
Maneuvering ofCS toward precision medicine for AML?
Splitting from a lump: harmonizing ALCL classification
The glycosaminoglycan oncofetal chondroitin sulfate is a novel target for antibody-drug conjugate therapy for AML
Abstract Antibody-drug conjugates (ADCs) have emerged as promising targeted therapies for acute myeloid leukemia (AML). However, most ADCs exhibit off-target binding to normal hema...